Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.480
Open
1.470
VWAP
1.47
Vol
28.36K
Mkt Cap
72.10M
Low
1.470
Amount
41.74K
EV/EBITDA(TTM)
--
Total Shares
49.05M
EV
31.74M
EV/OCF(TTM)
--
P/S(TTM)
--
MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), prevention of acute respiratory distress syndrome (ARDS), and Long COVID, and MN-001 (tipelukast) for fibrotic and other diseases, such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.
Show More
Valuation Metrics
The current forward P/E ratio for MediciNova Inc (MNOV.O) is -2.94, compared to its 5-year average forward P/E of -10.05. For a more detailed relative valuation and DCF analysis to assess MediciNova Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-10.05
Current PE
-2.94
Overvalued PE
-1.70
Undervalued PE
-18.40
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
2.22
Current EV/EBITDA
-5.14
Overvalued EV/EBITDA
9.87
Undervalued EV/EBITDA
-5.43
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
46.21
Current PS
0.00
Overvalued PS
130.57
Undervalued PS
-38.16
Financials
Annual
Quarterly
FY2024Q4
0.00
Total Revenue
FY2024Q4
YoY :
+27.85%
-3.18M
Operating Profit
FY2024Q4
YoY :
+36.69%
-2.81M
Net Income after Tax
FY2024Q4
YoY :
+50.00%
-0.06
EPS - Diluted
FY2024Q4
YoY :
+287.07%
-1.93M
Free Cash Flow
FY2024Q4
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2024Q4
YoY :
-100.00%
N/A
FCF Margin - %
FY2024Q4
YoY :
-100.00%
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
MNOV News & Events
Events Timeline
2025-04-08 (ET)
2025-04-08
19:03:16
MediciNova says first patient enrolled in EAP trial to evaluate MN-166
2024-11-19 (ET)
2024-11-19
08:11:54
MediciNova provides update in letter to stockholders
2024-11-14 (ET)
2024-11-14
17:03:27
MediciNova granted Notice of Allowance for MN-001 patent by USPTO
Sign Up For More Events
Sign Up For More Events
News
1.0
04-14NewsfilterMediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025
9.0
04-08NewsfilterFirst Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients
9.0
04-08Business InsiderMediciNova says first patient enrolled in EAP trial to evaluate MN-166
Sign Up For More News
People Also Watch
NVX
NOVONIX Ltd
1.260
USD
+2.44%
HDSN
Hudson Technologies Inc
7.460
USD
-4.36%
ATGL
Alpha Technology Group Ltd
24.300
USD
-8.75%
ONIT
Onity Group Inc
37.840
USD
+0.80%
FLIC
First of Long Island Corp
12.340
USD
-0.40%
OSUR
OraSure Technologies Inc
2.510
USD
-3.46%
EM
Smart Share Global Ltd
1.100
USD
+1.85%
DBI
Designer Brands Inc
3.300
USD
+0.30%
LEGT
Legato Merger Corp III
10.580
USD
-0.19%
BYND
Beyond Meat Inc
2.280
USD
-2.56%
FAQ
What is MediciNova Inc (MNOV) stock price today?
The current price of MNOV is 1.47 USD — it has decreased -1.34 % in the last trading day.
What is MediciNova Inc (MNOV)'s business?
What is the price predicton of MNOV Stock?
What is MediciNova Inc (MNOV)'s revenue for the last quarter?
What is MediciNova Inc (MNOV)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for MediciNova Inc (MNOV)'s fundamentals?
How many employees does MediciNova Inc (MNOV). have?